Radiopharmaceuticals as orphan drugs

Seminars in Nuclear Medicine

Volumn 26, Issue 2, 1996, Pages 91-95

  Swanson, Dennis P ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b BCNP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOISOTOPE;

ARTICLE; CLASSIFICATION; DRUG MANUFACTURE; ECONOMICS; EPIDEMIOLOGY; FOOD AND DRUG ADMINISTRATION; GENERAL ASPECTS OF DISEASE; HUMAN; LEGAL ASPECT; NEOPLASM; RADIOGRAPHY; UNITED STATES;

DISEASE; EPIDEMIOLOGY; HUMANS; NEOPLASMS; ORPHAN DRUG PRODUCTION; RADIOISOTOPES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0030120053     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-2998(96)80030-4     Document Type: Article

References (8)

1. Out of darkness into the light (information pamphlet). New Fairfield, CT, National Organization for Rare Disorders, 1995
2. Orphan drug regulations: Final rule. Federal Register 57:62076-62092,1992
3. The Orphan Drug Act and its implementation: A program review (information sheet). Rockville, MD, Office of Orphan Products Development, Food and Drug Administration, 1995
4. Clinical studies of safety and effectiveness of orphan products; Availability of grants; Request for applications. Federal Register 59:41769-41772,1994
5. Clinical studies of safety and effectiveness of orphan products; Availability of grants; Request for applications. Federal Register 60:32527,1995
6. Office of Orphan Products Development (HF-35). Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857
7. USP DI (ed 15). Rockville, MD, United States Pharmacopeia! Convention, Inc., 1995
8. National Organization for Rare Disorders. PO Box 8923, New Fairfield, CT 06812-8923, Phone (203) 746-6518